Patents by Inventor Brian Alan Lanman

Brian Alan Lanman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds that inhibits MCL-1 protein
    Patent number: 11224601
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: January 18, 2022
    Assignee: AMGEN INC.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20220002298
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: September 22, 2021
    Publication date: January 6, 2022
    Inventors: Jian CHEN, Nuria A. TAMAYO, Longbin LIU, Hui-Ling WANG, Brian Alan LANMAN, Ryan Paul WURZ, Youngsook SHIN, Victor J. CEE
  • APELIN POLYPEPTIDES
    Publication number: 20210261619
    Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
    Type: Application
    Filed: January 28, 2021
    Publication date: August 26, 2021
    Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Michael J. FROHN, Brian Alan LANMAN, Anthony B. REED, Leslie P. MIRANDA, John Gordon ALLEN, Alexander J. PICKRELL, Aaron C. SIEGMUND, Lewis D. PENNINGTON, Bryant YANG
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11096939
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: August 24, 2021
    Assignee: Amgen Inc.
    Inventors: Shon Booker, John Gordon Allen, Brian Alan Lanman, Ryan Paul Wurz, Ning Chen, Victor J. Cee, Patricia Lopez, Aaron C. Siegmund, Michael D. Bartberger
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11090304
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: August 17, 2021
    Assignee: Amgen Inc.
    Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11053226
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: July 6, 2021
    Assignee: AMGEN INC.
    Inventors: Youngsook Shin, Victor J. Cee, Christopher M. Tegley, Brian Alan Lanman, Ryan Paul Wurz, Kevin C. Yang, Vu Van Ma, Daniel Erlanson, Joon Won Jeong, Raymond V. Fucini, Jeffrey Iwig
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11045484
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: June 29, 2021
    Assignee: Amgen Inc.
    Inventors: Ryan Paul Wurz, Victor J. Cee, Albert Amegadzie, Ning Chen, Brian Alan Lanman, Michael D. Bartberger
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 10988485
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: April 27, 2021
    Assignee: Amgen Inc.
    Inventors: Ana Elena Minatti, Jonathan Dante Low, Ryan Paul Wurz, Brian Alan Lanman, Victor J. Cee, Michael D. Bartberger, Margaret Chu-Moyer
  • Apelin polypeptides
    Patent number: 10941182
    Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: March 9, 2021
    Assignee: Amgen Inc.
    Inventors: Jerry Ryan Holder, Gayathri Swaminath, Michael J. Frohn, Brian Alan Lanman, Anthony B. Reed, Leslie P. Miranda, John G. Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20210009577
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 14, 2021
    Inventors: Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, David John KOPECKY, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon BOOKER, Nobuko NISHIMURA, Youngsook SHIN, Nuria A. TAMAYO, John Gordon ALLEN, Jennifer Rebecca ALLEN
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20200360399
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: August 17, 2018
    Publication date: November 19, 2020
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, Kexue LI, Yunxiao LI, Anthony B. REED, Brian Alan LANMAN
  • Compounds that inhibit Mcl-1 protein
    Patent number: 10821115
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 3, 2020
    Assignee: AMGEN INC.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • MACROCYCLIC COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20200247821
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: August 27, 2018
    Publication date: August 6, 2020
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, Yunxiao LI, Paul E. HARRINGTON, Brian Alan LANMAN, Jonathan D. LOW, Ana Elena MINATTI, Vu Van MA, Kexue LI
  • INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME
    Publication number: 20200207766
    Abstract: Provided herein are methods of using KRAS G12C inhibitors. These methods of using the inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: March 12, 2020
    Publication date: July 2, 2020
    Inventors: Brian Alan LANMAN, Shon BOOKER, Clifford GOODMAN, Anthony B. REED, Jonathan D. LOW, Hui-Ling WANG, Ning CHEN, Ana Elena MINATTI, Ryan WURZ, Victor J. CEE
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20200171043
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 4, 2020
    Applicant: AMGEN INC.
    Inventors: Paul E. HARRINGTON, Kate ASHTON, Sean P. BROWN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Yunxiao LI, Jonathan D. LOW, Ana Elena MINATTI, Alexander J. PICKRELL, Markian M. STEC, Joshua TAYGERLY
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20200165231
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: November 18, 2019
    Publication date: May 28, 2020
    Inventors: Youngsook SHIN, Victor J. CEE, Christopher M. TEGLEY, Brian Alan LANMAN, Ryan Paul WURZ, Kevin C. YANG, Vu Van MA, Daniel ERLANSON, Joon Won JEONG, Raymond V. FUCINI, Jeffrey IWIG
  • Inhibitors of KRAS G12C and methods of using the same
    Patent number: 10640504
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: May 5, 2020
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Shon Booker, Clifford Goodman, Anthony B. Reed, Jonathan D. Low, Hui-Ling Wang, Ning Chen, Ana Elena Minatti, Ryan Wurz, Victor J. Cee
  • Compounds that inhibit Mcl-1 protein
    Patent number: 10632128
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: April 28, 2020
    Assignee: AMGEN INC.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20200069657
    Abstract: Provided herein are methods of treating cancer with KRAS G12C inhibitors and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: November 5, 2019
    Publication date: March 5, 2020
    Applicant: AMGEN INC.
    Inventors: Brian Alan LANMAN, Victor J. CEE, Alexander J. PICKRELL, Anthony B. REED, Kevin C. YANG, David John KOPECKY, Hui-Ling WANG, Patricia LOPEZ, Kate ASHTON, Shon BOOKER, Christopher M. TEGLEY
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20200055845
    Abstract: Provided herein are methods of using KRAS G12C inhibitors and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: October 23, 2019
    Publication date: February 20, 2020
    Inventors: Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, David John KOPECKY, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon BOOKER, Nobuko NISHIMURA, Youngsook SHIN, Nuria A. TAMAYO, John Gordon ALLEN, Jennifer Rebecca ALLEN